Im­munother­a­py biotech un­stealths with $13M; An­ti-in­fec­tion can­di­date for CF pass­es safe­ty tri­al

Shen­non Biotech­nolo­gies has raised $13 mil­lion in seed fund­ing for a sin­gle cell plat­form to cre­ate more ef­fec­tive im­munother­a­pies. The com­pa­ny says the plat­form can “pro­file mil­lions of im­mune cells func­tion­al­ly at the sin­gle cell lev­el with­in a few hours” in or­der to iden­ti­fy TCR or an­ti­body tar­gets.

“This tech­nol­o­gy has the po­ten­tial to over­come a key bot­tle­neck in im­munother­a­py by iden­ti­fy­ing rare anti­gen-spe­cif­ic im­mune cells through en­abling high-through­put analy­sis of func­tion­al pair­ing be­tween ef­fec­tor and tar­get cells in a way that was pre­vi­ous­ly im­pos­si­ble,” Joseph Frai­et­ta, a sci­en­tif­ic ad­vi­sor for Shen­non and di­rec­tor of the Sol­id Tu­mor Im­munother­a­py Lab at the Uni­ver­si­ty of Penn­syl­va­nia, said in a state­ment.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN